000179278 001__ 179278
000179278 005__ 20240229145538.0
000179278 0247_ $$2doi$$a10.1016/j.lungcan.2022.03.010
000179278 0247_ $$2pmid$$apmid:35334417
000179278 0247_ $$2ISSN$$a0169-5002
000179278 0247_ $$2ISSN$$a1872-8332
000179278 0247_ $$2altmetric$$aaltmetric:125391723
000179278 037__ $$aDKFZ-2022-00560
000179278 041__ $$aEnglish
000179278 082__ $$a610
000179278 1001_ $$aVan der Weijst, Lotte$$b0
000179278 245__ $$aOverview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
000179278 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2022
000179278 3367_ $$2DRIVER$$aarticle
000179278 3367_ $$2DataCite$$aOutput Types/Journal article
000179278 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1648641134_12909
000179278 3367_ $$2BibTeX$$aARTICLE
000179278 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179278 3367_ $$00$$2EndNote$$aJournal Article
000179278 520__ $$aRadiotherapy-induced toxicity may negatively impact health-related quality of life (HRQoL). This report investigates the impact of curative-intent radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small cell lung cancer patients treated with radiotherapy or chemo-radiotherapy enrolled in the observational prospective REQUITE study.HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities were scored by clinicians using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline values. Mixed model analyses were applied to determine statistical significance (p ≤ 0.01). Meaningful clinical important differences (MCID) were determined for changes in HRQoL. Analysis was performed on the overall data, different radiotherapy techniques, multimodality treatments and disease stages.Data of 510 patients were analysed. There was no significant change in HRQoL or its domains, except for deterioration in cognitive functioning (p = 0.01). Radiotherapy technique had no significant impact on HRQoL. The addition of chemotherapy was significantly associated with HRQoL over time (p <.001). Overall toxicity did not significantly change over time. Acute toxicities of radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated but improved significantly after 12 months (p =.011). A proportion of patients experienced meaningful clinically important improvements and deteriorations in overall HRQoL and its domains. In some patients, pre-treatment symptoms improved gradually.While overall HRQoL and toxicity did not change over time, some patients improved, whereas others experienced acute radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and cognitive functioning. Patient characteristics, more so than radiotherapy technique and treatment modality, impact post-radiotherapy toxicity and HRQoL outcomes. This stresses the importance of considering the potential impact of radiotherapy on individuals' HRQoL, symptoms and toxicity in treatment decision-making.
000179278 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179278 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179278 7001_ $$aAguado-Barrera, Miguel E$$b1
000179278 7001_ $$aAzria, David$$b2
000179278 7001_ $$aBerkovic, Patrick$$b3
000179278 7001_ $$aBoisselier, Pierre$$b4
000179278 7001_ $$aBriers, Erik$$b5
000179278 7001_ $$aBultijnck, Renée$$b6
000179278 7001_ $$aCalvo-Crespo, Patricia$$b7
000179278 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b8$$udkfz
000179278 7001_ $$aChoudhury, Ananya$$b9
000179278 7001_ $$aDefraene, Gilles$$b10
000179278 7001_ $$aDemontois, Sylvian$$b11
000179278 7001_ $$aDunning, Alison M$$b12
000179278 7001_ $$aElliott, Rebecca M$$b13
000179278 7001_ $$aEnnis, Dawn$$b14
000179278 7001_ $$aFaivre-Finn, Corinne$$b15
000179278 7001_ $$aFranceschini, Marzia$$b16
000179278 7001_ $$aGutiérrez-Enríquez, Sara$$b17
000179278 7001_ $$aHerskind, Carsten$$b18
000179278 7001_ $$aHigginson, Daniel S$$b19
000179278 7001_ $$aKerns, Sarah L$$b20
000179278 7001_ $$aJohnson, Kerstie$$b21
000179278 7001_ $$aMollà, Meritxell$$b22
000179278 7001_ $$aLambrecht, Maarten$$b23
000179278 7001_ $$aRamos, Mónica$$b24
000179278 7001_ $$aRancati, Tiziana$$b25
000179278 7001_ $$aRimner, Andreas$$b26
000179278 7001_ $$aRosenstein, Barry S$$b27
000179278 7001_ $$aDe Ruysscher, Dirk$$b28
000179278 7001_ $$aSalem, Ahmed$$b29
000179278 7001_ $$aSangalli, Claudia$$b30
000179278 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b31$$udkfz
000179278 7001_ $$aSosa-Fajardo, Paloma$$b32
000179278 7001_ $$aSperk, Elena$$b33
000179278 7001_ $$aStobart, Hilary$$b34
000179278 7001_ $$aSummersgill, Holly$$b35
000179278 7001_ $$aSurmont, Veerle$$b36
000179278 7001_ $$aSymonds, Paul$$b37
000179278 7001_ $$aTaboada-Lorenzo, Begoña$$b38
000179278 7001_ $$aTalbot, Christopher J$$b39
000179278 7001_ $$aValdagni, Riccardo$$b40
000179278 7001_ $$aVega, Ana$$b41
000179278 7001_ $$aVeldeman, Liv$$b42
000179278 7001_ $$aVeldwijk, Marlon R$$b43
000179278 7001_ $$aWard, Tim$$b44
000179278 7001_ $$aWebb, Adam$$b45
000179278 7001_ $$aWest, Catharine M L$$b46
000179278 7001_ $$aConsortium, REQUITE$$b47$$eCollaboration Author
000179278 7001_ $$aLievens, Yolande$$b48
000179278 773__ $$0PERI:(DE-600)2025812-4$$a10.1016/j.lungcan.2022.03.010$$gVol. 166, p. 228 - 241$$p228 - 241$$tLung cancer$$v166$$x0169-5002$$y2022
000179278 909CO $$ooai:inrepo02.dkfz.de:179278$$pVDB
000179278 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000179278 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000179278 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179278 9141_ $$y2022
000179278 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000179278 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000179278 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000179278 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLUNG CANCER : 2021$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000179278 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLUNG CANCER : 2021$$d2022-11-11
000179278 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000179278 980__ $$ajournal
000179278 980__ $$aVDB
000179278 980__ $$aI:(DE-He78)C020-20160331
000179278 980__ $$aUNRESTRICTED